CEACAM-Targeting Monoclonal Antibodies with Unique CDR Sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies recognizing CEACAM1 lack the spectrum of binding specificity needed for effective therapeutic and diagnostic applications in diseases involving CEACAM expression or activation, particularly in malignancies and viral infections.
Innovation Solution
Development of monoclonal antibodies with unique complementarity determining regions (CDRs) that specifically bind to CEACAM1 and additional subtypes like CEACAM5 and CEACAM3, offering improved specificity and potency, and methods for their production and use in therapeutic and diagnostic contexts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing antibodies are used to recognize CEACAM1, then they can bind to the antigen, but they lack sufficient binding specificity for effective therapeutic and diagnostic applications
Solution Approach 1:
The patent applies parameter changes by modifying the antibody sequences, specifically the complementarity determining regions (CDRs), to alter their binding characteristics. The invention provides multiple antibody sequences with modified CDR regions that enhance specificity for CEACAM1 and related subtypes, thereby resolving the contradiction between binding capability and binding specificity.
2Adaptability or versatility
If antibodies with broader binding specificity are developed, then therapeutic and diagnostic utility is improved, but the complexity of antibody characterization and selection increases
Solution Approach 1:
The patent applies universality by providing a family of antibodies that can recognize multiple CEACAM subtypes (CEACAM1, CEACAM3, CEACAM5, CEACAM6) through conserved epitopes. This multi-specificity allows a single antibody family to serve multiple diagnostic and therapeutic purposes across different disease states, reducing the need for entirely separate antibody developments for each application.
Solution Approach 2:
The patent systematically varies antibody sequences, particularly in the CDR regions, to optimize binding characteristics for different CEACAM subtypes. By parameterizing the antibody sequences and providing specific sequence information, the invention enables tailored antibody selection without requiring de novo characterization of each variant, thus managing complexity while achieving versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibodies provide enhanced therapeutic utility and diagnostic capabilities by specifically targeting CEACAM subtypes, improving treatment outcomes for malignancies and viral infections, and inhibiting CEACAM-mediated interactions, thereby modulating immune responses effectively.
Implementation Method 1
monoclonal antibodies which recognize a specific set of CEACAM subtypes... show binding to CEACAM1 and at least one additional subtype
Data Source
AI summary
The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.